LMAT vs. NVCR, ATEC, ATRC, MDXG, AORT, FNA, SILK, NARI, ATRI, and KIDS
Should you be buying LeMaitre Vascular stock or one of its competitors? The main competitors of LeMaitre Vascular include NovoCure (NVCR), Alphatec (ATEC), AtriCure (ATRC), MiMedx Group (MDXG), Artivion (AORT), Paragon 28 (FNA), Silk Road Medical (SILK), Inari Medical (NARI), Atrion (ATRI), and OrthoPediatrics (KIDS). These companies are all part of the "surgical & medical instruments" industry.
LeMaitre Vascular (NASDAQ:LMAT) and NovoCure (NASDAQ:NVCR) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, profitability, media sentiment, community ranking, earnings and dividends.
LeMaitre Vascular has a beta of 0.88, suggesting that its stock price is 12% less volatile than the S&P 500. Comparatively, NovoCure has a beta of 0.5, suggesting that its stock price is 50% less volatile than the S&P 500.
LeMaitre Vascular received 34 more outperform votes than NovoCure when rated by MarketBeat users. Likewise, 70.96% of users gave LeMaitre Vascular an outperform vote while only 63.71% of users gave NovoCure an outperform vote.
LeMaitre Vascular has higher earnings, but lower revenue than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks.
In the previous week, LeMaitre Vascular had 7 more articles in the media than NovoCure. MarketBeat recorded 28 mentions for LeMaitre Vascular and 21 mentions for NovoCure. LeMaitre Vascular's average media sentiment score of 0.61 beat NovoCure's score of 0.06 indicating that LeMaitre Vascular is being referred to more favorably in the media.
LeMaitre Vascular presently has a consensus target price of $73.83, suggesting a potential downside of 0.52%. NovoCure has a consensus target price of $30.88, suggesting a potential upside of 108.90%. Given NovoCure's higher probable upside, analysts plainly believe NovoCure is more favorable than LeMaitre Vascular.
84.6% of LeMaitre Vascular shares are held by institutional investors. Comparatively, 84.6% of NovoCure shares are held by institutional investors. 10.8% of LeMaitre Vascular shares are held by insiders. Comparatively, 5.7% of NovoCure shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
LeMaitre Vascular has a net margin of 16.99% compared to NovoCure's net margin of -36.67%. LeMaitre Vascular's return on equity of 11.57% beat NovoCure's return on equity.
Summary
LeMaitre Vascular beats NovoCure on 15 of the 17 factors compared between the two stocks.
Get LeMaitre Vascular News Delivered to You Automatically
Sign up to receive the latest news and ratings for LMAT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LMAT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
LeMaitre Vascular Competitors List
Related Companies and Tools
